Literature DB >> 23970349

8-bromo-5-hydroxy-7-methoxychrysin targeting for inhibition of the properties of liver cancer stem cells by modulation of Twist signaling.

Kai-Qun Ren1, Xiao-Zheng Cao, Zhi-Hong Liu, Hui Guo, Mei-Fang Quan, Fei Liu, Ling Jiang, Hong-Lin Xiang, Xi-Yun Deng, Jian-Guo Cao.   

Abstract

Emerging evidence has suggested that cancer stem cells with expression of surface biomarkers including CD133 and CD44 have more aggressive biological behavior, including epithelial-mesenchymal transition (EMT), which are closely related to invasion. The upregulation and nuclear relocation of the EMT regulator Twist1 have been implicated in the tumor invasion and metastasis of human hepatocellular carcinoma (HCC). In this study, we aimed to isolate and characterize a small population of CD133+ cells that existed in the HCC cell line SMMC-7721 by MACS and investigated the possible roles of 8-bromo-7-methoxychrysin (BrMC), a synthetic analogue of chrysin, in inhibiting the properties of CD133+ sphere-forming cells (SFCs) derived from the HCC cell line SMMC-7721, namely liver cancer stem cells (LCSCs). Based on the data, BrMC inhibited the proliferation, self-renewal and invasion of LCSCs in vitro and in vivo, downregulated the expression of the LCSC biomarkers CD133 and CD44 and induced EMT by downregulating the expression of Twist and β-catenin in LCSCs. BrMC potentiated the inhibition of LCSCs self-renewal after reduction of twist protein levels, which was attenuated when twist was overexpressed. This study not only provides an important experimental and theoretical basis for investigation of BrMC in LCSCs, but also helps in the development of effective therapeutic medicine for HCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23970349     DOI: 10.3892/ijo.2013.2071

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

Review 1.  Twist in hepatocellular carcinoma: pathophysiology and therapeutics.

Authors:  Hui Zou; Xing Feng; Jian-Guo Cao
Journal:  Hepatol Int       Date:  2015-05-28       Impact factor: 6.047

2.  Deciphering the molecular mechanisms underlying the binding of the TWIST1/E12 complex to regulatory E-box sequences.

Authors:  Charlotte Bouard; Raphael Terreux; Mylène Honorat; Brigitte Manship; Stéphane Ansieau; Arnaud M Vigneron; Alain Puisieux; Léa Payen
Journal:  Nucleic Acids Res       Date:  2016-05-05       Impact factor: 16.971

3.  Lovastatin Inhibits Cancer Stem Cells and Sensitizes to Chemo- and Photodynamic Therapy in Nasopharyngeal Carcinoma.

Authors:  Yikun Peng; Guangchun He; Da Tang; Li Xiong; Yu Wen; Xiongying Miao; Zhangyong Hong; Hui Yao; Chao Chen; Shichao Yan; Lu Lu; Yingke Yang; Qinglong Li; Xiyun Deng
Journal:  J Cancer       Date:  2017-06-03       Impact factor: 4.207

4.  Upregulation of FoxM1 by MnSOD Overexpression Contributes to Cancer Stem-Like Cell Characteristics in the Lung Cancer H460 Cell Line.

Authors:  Zhimin Fu; Xiaocheng Cao; Yi Yang; Zhenwei Song; Jiansong Zhang; Zheng Wang
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

Review 5.  Targeting liver cancer stem cells for the treatment of hepatocellular carcinoma.

Authors:  Na Li; Ying Zhu
Journal:  Therap Adv Gastroenterol       Date:  2019-01-22       Impact factor: 4.409

6.  8-bromo-7-methoxychrysin targets NF-κB and FoxM1 to inhibit lung cancer stem cells induced by pro-inflammatory factors.

Authors:  Qing Yuan; Min Wen; Chang Xu; A Chen; Ye-Bei Qiu; Jian-Guo Cao; Jian-Song Zhang; Zhen-Wei Song
Journal:  J Cancer       Date:  2019-08-28       Impact factor: 4.207

7.  Isovitexin Suppresses Stemness of Lung Cancer Stem-Like Cells through Blockage of MnSOD/CaMKII/AMPK Signaling and Glycolysis Inhibition.

Authors:  Fei Liu; Qing Yuan; Xiaocheng Cao; Jinlin Zhang; Jianguo Cao; Jiansong Zhang; Liqiu Xia
Journal:  Biomed Res Int       Date:  2021-05-24       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.